ES3002193T3 - Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate - Google Patents
Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate Download PDFInfo
- Publication number
- ES3002193T3 ES3002193T3 ES21734241T ES21734241T ES3002193T3 ES 3002193 T3 ES3002193 T3 ES 3002193T3 ES 21734241 T ES21734241 T ES 21734241T ES 21734241 T ES21734241 T ES 21734241T ES 3002193 T3 ES3002193 T3 ES 3002193T3
- Authority
- ES
- Spain
- Prior art keywords
- saponin
- galnac
- xyl
- rha
- fuc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025899 | 2020-06-24 | ||
| NL2026442 | 2020-09-10 | ||
| PCT/NL2021/050384 WO2021261992A1 (en) | 2020-06-24 | 2021-06-18 | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3002193T3 true ES3002193T3 (en) | 2025-03-06 |
Family
ID=76584529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21734241T Active ES3002193T3 (en) | 2020-06-24 | 2021-06-18 | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230263897A1 (cg-RX-API-DMAC10.html) |
| EP (3) | EP4171641B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023532040A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230043114A (cg-RX-API-DMAC10.html) |
| CN (2) | CN116234582A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2026202914A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3002193T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL299357A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023000092A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021261992A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114072503A (zh) * | 2019-07-02 | 2022-02-18 | 阿尔戈诺特Rna有限公司 | 载脂蛋白b拮抗剂 |
| CN117355534B (zh) | 2021-01-30 | 2026-05-01 | 唐格拉姆治疗公司 | 缀合寡核苷酸化合物、其制备方法和用途 |
| WO2022162157A1 (en) * | 2021-01-30 | 2022-08-04 | E-Therapeutics Plc | Conjugated oligonucleotide compounds, methods of making and uses thereof |
| CN115227700B (zh) * | 2022-06-09 | 2024-03-19 | 大连医科大学 | 商陆皂苷甲在制备心肌梗死保护药物中的应用 |
| JP2026519131A (ja) * | 2023-06-02 | 2026-06-11 | サプリーム テクノロジーズ,ベー.フェー. | 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン |
| TW202504619A (zh) * | 2023-07-20 | 2025-02-01 | 大陸商上海舶望製藥有限公司 | 用於抑制pd-l1表達的組合物和方法 |
| CN116655715B (zh) * | 2023-07-27 | 2023-10-20 | 北京炫景瑞医药科技有限公司 | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 |
| CN116854754B (zh) * | 2023-09-01 | 2023-12-12 | 北京悦康科创医药科技股份有限公司 | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 |
| WO2025090612A1 (en) * | 2023-10-27 | 2025-05-01 | Wisconsin Alumni Research Foundation | Lipid nanoparticles formed by lipidoids for efficient delivery of nucleotide drugs and biologics |
| WO2026087680A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for cardiovascular disease |
| WO2026087678A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for renal disorders |
| WO2026087695A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for metabolic disorder |
| WO2026119464A1 (en) | 2024-12-03 | 2026-06-11 | Sapreme Technologies B.V. | Treatment for cns-related disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275954A1 (en) * | 2002-11-08 | 2004-06-07 | Danmarks Fodevareforskning | Preparation of chemically well-defined carbohydrate dendrimer conjugates |
| ES2395818T3 (es) * | 2004-07-13 | 2013-02-15 | Charite - Universitatsmedizin Berlin | Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina |
| WO2008007941A1 (en) * | 2006-07-10 | 2008-01-17 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Gainac specific binding molecules and uses thereof |
| WO2011054811A1 (en) * | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| WO2011141703A1 (en) * | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| WO2011156751A2 (en) * | 2010-06-11 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | Immunogenic vaccine |
| US20150024037A1 (en) * | 2012-02-16 | 2015-01-22 | The University Of Toledo | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| AR100516A1 (es) * | 2014-05-19 | 2016-10-12 | Pfizer | Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr |
| AU2015329974B2 (en) * | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
| EP3514240A1 (en) * | 2018-01-18 | 2019-07-24 | Freie Universität Berlin | Novel uses of a saponin and method for its isolation |
| US20220023433A1 (en) * | 2018-12-21 | 2022-01-27 | Sapreme Technologies B.V. | Saponin Conjugates |
-
2021
- 2021-06-18 US US18/012,769 patent/US20230263897A1/en active Pending
- 2021-06-18 EP EP21734241.9A patent/EP4171641B1/en active Active
- 2021-06-18 EP EP26184555.6A patent/EP4782067A2/en active Pending
- 2021-06-18 KR KR1020237002660A patent/KR20230043114A/ko active Pending
- 2021-06-18 CN CN202180051254.4A patent/CN116234582A/zh active Pending
- 2021-06-18 MX MX2023000092A patent/MX2023000092A/es unknown
- 2021-06-18 WO PCT/NL2021/050384 patent/WO2021261992A1/en not_active Ceased
- 2021-06-18 IL IL299357A patent/IL299357A/en unknown
- 2021-06-18 EP EP24190153.7A patent/EP4438125A3/en active Pending
- 2021-06-18 JP JP2022580236A patent/JP2023532040A/ja active Pending
- 2021-06-18 ES ES21734241T patent/ES3002193T3/es active Active
- 2021-06-18 CN CN202510833809.0A patent/CN120586078A/zh active Pending
-
2026
- 2026-04-17 AU AU2026202914A patent/AU2026202914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL299357A (en) | 2023-02-01 |
| EP4438125A3 (en) | 2024-12-25 |
| CN116234582A (zh) | 2023-06-06 |
| JP2023532040A (ja) | 2023-07-26 |
| CN120586078A (zh) | 2025-09-05 |
| WO2021261992A1 (en) | 2021-12-30 |
| KR20230043114A (ko) | 2023-03-30 |
| EP4782067A2 (en) | 2026-07-29 |
| AU2026202914A1 (en) | 2026-05-07 |
| EP4438125A2 (en) | 2024-10-02 |
| US20230263897A1 (en) | 2023-08-24 |
| EP4171641A1 (en) | 2023-05-03 |
| EP4171641B1 (en) | 2024-10-30 |
| EP4171641C0 (en) | 2024-10-30 |
| MX2023000092A (es) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4171641B1 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| US20240307545A1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| WO2022055351A1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| WO2021261998A1 (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| EP4171643B1 (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| EP4210760B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2021295358B2 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| HK40116734A (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate | |
| HK40128805A (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| HK40129944A (zh) | Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物 | |
| HK40124033A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2021339332A1 (en) | Conjugate of saponin, oligonucleotide and GalNAc | |
| HK40091234B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| IL325054A (en) | Improved treatment regimens for therapeutic effector components acting through an intracellular molecular target |